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Persistent induction of nitric oxide synthase in
tumours from mice treated with the anti-tumour agent
5,6-dimethylxanthenonem4-acetic acid
E Moilanen', LL Thomsen', DW Miles2, L Happerfield2, RG Knowles' and S Moncada'
'Wellcome Research Laboratories, Langley Court, Beckenham, Kent BR3 3BS, UK; 21CRF Clinical Oncology Unit, Guy's Hospital, London SE1 9RT, UK
Summary An anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (5,6-MeXAA) induced nitric oxide synthase (NOS) in the tumour,
spleen, thymus and small intestine, but not in the lung, liver, kidney, heart or skeletal muscle in B6D2F1 mice bearing subcutaneous colon 38
tumours. This pattern of induction is distinct from that caused by agents such as endotoxin, muramyl dipeptide or Corynebacterium parvum.
The induction of NOS (iNOS) in the tumour was more persistent (maximal at 3 days) than in other tissues (maximal at 12 h).
Immunohistochemical staining suggested that iNOS was located in macrophages and endothelial cells within and around the tumour.
Treatment with 5,6-MeXAA also caused substantial increases in plasma nitrite and nitrate (NOx) concentrations that peaked at 8-12 h after
5,6-MeXAA. The increase in plasma NOx was prevented by a NOS inhibitor N-iminoethyl-L-ornithine (L-NIO), indicating that it was due to
enhanced production of NO. Tumour-bearing mice were more responsive than controls to 5,6-MeXAA both in their plasma NOx increase and
in their lower maximally tolerated dose. L-NIO was unable to prevent the complete tumour necrosis and regression caused by 5,6-MeXAA at
a dose that substantially inhibited the increase of plasma NOx. In conclusion, the experimental anti-tumour agent 5,6-MeXAA induced NO
synthesis in tumour-associated macrophages and in immunologically active tissues in parallel with its effects on tumour growth. The
experiments with a non-selective NOS inhibitor L-NIO, however, suggest that NO is not a significant component in the mechanism of the anti-
tumour action of 5,6-MeXAA in this particular model.
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A flavonoid derivative 5,6-dimethylxanthenone-4-acetic acid (5,6-
MeXAA) has proved to be a potent anti-tumour agent against solid
murine tumours (Rewcastle et al, 1991) and has been selected as a
candidate for clinical trials. The detailed mechanism of its anti-
tumour action is not known but several host-mediated responses
seem to be involved. 5,6-MeXAA and its parent compound flavone
acetic acid induce ischaemic haemorrhagic necrosis in subcuta-
neously growing tumours in mice (Zwi et al, 1989; Rewcastle et al,
1991). In addition, 5,6-MeXAA has stimulatory effects on the
immune response that could contribute to its anti-tumour action.
5,6-MeXAA stimulates the tumoricidal activity of both resident
and activated mouse peritoneal macrophages in vitro (Ching et al,
1992). 5,6-MeXAA augments synthesis of nitric oxide (NO) and
certain cytokines in vitro and in vivo (Thomsen et al, 1990; 1991;
Futami et al, 1992; Ching et al, 1994a,b; Perera et al, 1994). The
expression by mRNA of tumour necrosis factor (TNF) and/or the
synthesis of TNF protein after 5,6-MeXAA treatment has been
documented in murine macrophages, spleen cells, human HL-60
myelomonocytic cell line and in tumour-bearing mice (Futami et
al, 1992; Ching et al, 1994a,b, Perera et al, 1994). Activation of
some other lipopolysaccharide (LPS)-inducible genes as well as
interferons and interferon regulatory factors by 5,6-MeXAA has
been reported in primary murine macrophages (Perera et al, 1994).
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Nitric oxide (NO) is a signalling molecule synthesized from L-
arginine by a family of NO synthase (NOS) enzymes (Knowles
and Moncada, 1994). NO has been shown to display several
actions that significantly modify tumour growth. NO inhibits
proliferation of tumour cells (Lepoivre et al, 1989; Maragos et al,
1993; Jenkins et al, 1995) and tumour-infiltrating lymphocytes
(Lejeune et al, 1994). It also induces apoptosis in malignant cells
and reduces formation of metastases (Xie et al, 1995a,b). In vivo,
synthesis of NO at low levels stimulates angiogenesis leading to
accelerated tumour growth (Jenkins et al, 1995). Treatment with
5,6-MeXAA induces NO synthesis in tumour-bearing and in
healthy mice (Thomsen et al, 1990, 1991). NO synthesis,
measured by an increase in its oxidation products in plasma, in
response to 5,6-MeXAA and chemical analogues offlavone acetic
acid correlates with the delay in tumour growth caused by these
agents in a colon 38 tumour model in mice (Thomsen et al, 1991).
Mouse peritoneal macrophages activated by Bacillus Calmette-
Guerin synthesized NO in response to 5,6-MeXAA in vitro
(Thomsen et al, 1990). The aim ofthe present study was to inves-
tigate the profile of 5,6-MeXAA-induced NO synthesis in tumour
and other tissues and the relationship between NO synthesis and
the anti-tumour action of 5,6-MeXAA in immunocompetent mice
bearing subcutaneous colon 38 tumours.
MATERIALS AND METHODS
Materials
5,6-MeXAA was synthesized at the Cancer Research Laboratory,
University ofAuckland, Auckland, New Zealand (Rewcastle et al,
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Table 1 NOS activity in tissues before (control) and 12 h after treatment
with 5,6-MeXAA (27.5 mg kg-' i.p.) in tumour-bearing B6D2F1 mice
Tissue NOS (pmol min-' mg-' protein; mean ± s.e.m.a)
Total Ca2+-dependent Ca2+-independent
Tumour
Control 1.5 ± 0.4 0.2 ± 0.1 1.3 ± 0.4
12 h 8.6 ± 2.1**b 0.8 ± 0.3 7.8 ± 1.9**
Spleen
Control 0.7 ± 0.2 0.4 ± 0.1 0.3 ± 0.2
12 h 4.9 ±0.7*** 0.8 ± 0.2 4.1 ±0.6***
Thymus
Control 1.9 ± 1.2 1.0 ± 1.0 1.0 ± 0.4
12 h 5.3± 1.0* 0.8 ± 0.7 4.5 ± 0.5**
Intestine
Control 0.5±0.2 0.2±0.1 0.3±0.1
12h 2.3±0.3*** 0.5±0.2 1.8±0.3***
Lung
Control 3.1 ± 0.5 2.6 ± 0.4 0.5 ± 0.1
12h 3.4±0.6 2.7±0.2 0.7±0.3
Kidney
Control 3.3 ± 0.3 2.4 ± 0.2 0.9 ± 0.1
12h 3.4±0.3 2.6±0.3 0.8±0.1
Skeletal muscle
Control 7.3 ± 1.2 3.8 ± 0.7 3.5 ± 0.7
12h 7.1 ± 1.3 3.9± 1.6 2.9±0.7
Liver
Control 3.6 ± 1.0 NDc ND
12h 4.0±2.2 ND ND
Heart
Control 0.2± 0.1 ND ND
12h 0.6±0.4 ND ND
a5 or 6 mice per group; bdifferences between corresponding values before
and 12 h after 5,6-MeXAA are denoted by *P< 0.05, **P < 0.01 and
***P < 0.001; cND, not determined.
1991), and was a generous gift from Professor BC Baguley.
N-iminoethyl-L-omithine (L-NIO) and A0-monomethyl-L-arginine
(L-NMMA) were synthesized by the Department of Medicinal
Chemistry at the Wellcome Research Laboratories, Beckenham,
UK. L-[U'4C]Arginine was purchased from Amersham
(Buckinghamshire, UK), cell culture reagents from Gibco
(Paisley, UK), reagents for immunohistochemistry from Dako
(Bucks, UK) and other chemicals were from Sigma, Boehringer
Mannheim or BDH unless otherwise indicated.
Animal procedures
B6D2F1 mice were purchased from Harlan, Oxon, UK and housed
at a constant temperature and humidity with regular 12-h cycles of
light and darkness, sterile bedding, water and food. All experi-
ments were carried out under institutional ethical guidelines. In
experiments with tumour-bearing animals, colon 38 tumours were
implanted subcutaneously and allowed to grow to a diameter of
5-10 mm before use. 5,6-MeXAA was dissolved in 5% bicar-
bonate and administered as a single intraperitoneal (i.p.) or sub-
cutaneous (s.c.) injection. Lipopolysaccharide (LPS) (4 mg kg-',
TCA extract of Salmonella typhimurium, Sigma) and killed
Corynebacterium parvum organisms (100 mg kg-', Wellcome)
were dissolved in sterile phosphate-buffered saline (PBS) and
injected i.p. After the time interval indicated, mice were anaes-
thetized with halothane and blood was collected into heparinized
tubes. Animals were killed by cervical dislocation, resident peri-
toneal macrophages were harvested in sterile PBS (5 ml per
mouse) and tissues collected and snap-frozen in liquid nitrogen.
When tumour growth was studied, tumours were measured for
length and width by calipers every second day after treatment with
5,6-MeXAA. The tumour volume was estimated using the
formula: tumour volume = 0.52 x length x width2.
Measurement of NOS activity in tissues
Frozen tissues were thawed in ice-cold 20 mm Hepes buffer (pH
7.2) containing 200 mm sucrose, 0.1 mm EDTA, 5 mM dithio-
threitol, 10 ,ug ml-' leupeptin, 10 jg ml-' soyabean trypsin
inhibitor and 1 jg ml-' pepstatin A and homogenized (with an
Ystral homogenizer) in ice. The homogenates were centrifuged at
10 000g at 2°C for 30 min. Supernatants were treated with equal
volume of cation-exchange resin (Dowex-SOW, sodium form) to
remove endogenous arginine. NOS activity in the supernatants
(cytosol + microsomes) was measured by the conversion of L-[U-
14C]arginine to [U-'4C]citrulline at 37°C for 10 min in 20 mm
Hepes buffer (pH 7.2) containing 10gM tetrahydrobiopterin,
2.5 mm dithiothreitol, 400 U ml-' calmodulin, 250 jM calcium
chloride, 0.5 mg ml-' bovine serum albumin, 125 jiM NADPH,
10 ,UM arginine, 100 jiM citrulline, 60 m-im valine (to inhibit
arginase) and 0.33 jCi ml-' L-[U-'4C]arginine, as described previ-
ously (Salter et al, 1991). The total NOS activity was determined
from the difference between the [U-'4C]citrulline generated in
control samples and samples containing 1 mM L-NMMA; the
activity of the calcium-dependent NOS activity was determined
from the difference between control samples and samples
containing 1 mM EGTA, and the activity of calcium-independent
NOS was determined from the difference between samples
containing 1 mM EGTA and those with 1 mM L-NMMA. In liver
supematants, addition ofEGTA resulted in an anomalous apparent
increase in NOS activity, so that it was not possible to determine
the calcium-dependent and calcium-independent NOS activities
separately. Protein content ofthe tissue supematants was measured
by Coomassie brilliant blue assay (Bio-Rad) using bovine plasma
albumin as a standard.
Measurement of NOS activity in peritoneal
macrophages
The peritoneal cells were spun down and resuspended in
Dulbecco's modification of Eagle medium containing 100 jM
L-arginine, 10% heat-inactivated fetal calf serum, penicillin
(100 U ml-') and streptomycin (100 U ml-'). The macrophages
were allowed to adhere on tissue culture plates for 2 h. Thereafter,
the plates were washed twice with sterile PBS to remove non-
adherent cells. The adherent cells were harvested with a plastic
scraper into homogenization buffer and snap-frozen in liquid
nitrogen. NOS activity in the cytosol was measured as described
above, except that the cells were disrupted by sonication instead of
mechanical homogenization. Macrophages from six mice were
pooled to obtain each value.
Immunocytochemistry
Sections (5 jm thick) were cut from frozen tissue, air dried for
30 min and fixed for a further 30 min in acetone. Endogenous
peroxidase was visualized with 0.05% DAB (Diaminobenzidene)
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Figure 1 Time courses of the stimulatory action of 5,6-MeXAA (27.5 mg kg-' i.p.) on plasma NOx concentrations (0) and on NOS activity in thymus (0), spleen
(V) and in tumour (U in the inset) in tumour-bearing B6D2F1 mice. Mean ± s.e.m. (n = 6)
and non-specific binding sites were blocked with 20% normal
rabbit or swine sera for 15 min. A polyclonal primary antibody
against murine iNOS raised in rabbit (Anti-macNOS, Transduction
Laboratories, Lexington, KY, USA) was used at a 1:50 dilution to
detect iNOS. A rat antibody against murine CD31 (Clone 390,
Pharmingen, c/o Cambridge Biosciences, Cambridge, UK) was
applied at a 1:100 dilution for the detection of endothelial cells
(PECAM-1). For the demonstration of murine macrophages,
MOMA-2 (Serotec, Oxford, UK) was used at a dilution of 1:10.
The tissue sections were incubated with the optimally diluted
primary antibody for 30 min at room temperature. Slides were then
washed in Tris-buffered saline, and covered with biotinylated
rabbit anti-rat IgG or swine anti-rabbit IgG. After further rinsing,
slides were incubated with horseradish peroxidase-conjugated
streptavidin. The slides were then developed using aminoethylcar-
bizole and counterstained with haematoxylin.
Plasma nitrite + nitrate (NOx) assays
Plasma samples were diluted with distilled water, and proteins
were precipitated with zinc sulphate. Nitrate was reduced to nitrite
with acid-washed cadmium (Davison et al, 1978), and thereafter
nitrite concentrations were measured using a microplate assay
based on the Griess reaction (Green et al, 1982).
TNF and other parameters measured in plasma
TNF concentrations in the plasma were measured by enzyme-
linked immunosorbent assay (ELISA), as described previously
(Deakin et al, 1995). Plasma urea concentrations were assayed by
using a colorimetric kit for urea nitrogen (Sigma). Creatinine,
glutamate dehydrogenase (GLDH) and alanine transferase (ALT)
levels were assayed in plasma samples using standard clinical
chemistry methods using a Roche Cobas Biocentrifugal Analyser.
Statistics
Results are expressed as means ± standard error of the mean
(s.e.m.). When indicated, statistical significance was calculated by
analysis ofvariance supported by Bonferroni adjusted significance
levels. Differences were considered significant when P < 0.05.
RESULTS
Induction of NOS activity in tissues
NOS activity in tissue extracts was measured 12 h after 5,6-
MeXAA (27.5 mg kg-' i.p.) administration, which represents the
peak level of plasma NOx in tumour-bearing animals (see below).
Calcium-independent NOS activity was increased in the tumour,
spleen, thymus and small intestine, whereas NOS activity in the
lung, liver, kidney, heart and skeletal muscle was unchanged (Table
1). The time-courses of NOS activity in the spleen, thymus and
tumour were measured. NOS activities in the thymus and spleen
peaked at 12 h after treatment with 5,6-MeXAA and decreased
thereafter, mimicking the time-course of increases in plasma NOx
(Figure 1). NOS activity in the tumour, however, continued to
increase up to 3 days after 5,6-MeXAA treatment (Figure 1). The
peak NOS activity in.the tumours (25 pmol min-' mg-' protein) was
higher than that ofany ofthe other tissues studied.
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Figure 2 Immunohistochemical studies of tumour tissue. Sections of tumour tissue before treatment with 5,6-MeXAA, labelled with antibody against iNOS (A)
and (C), endothelial cells CD31 (B) and macrophage marker MOMA-2 (D), showing iNOS localized to endothelial cells within the tumour and in some
macrophages in the tumour capsule. Sections of tumour tissue taken 3 days after treatment, immunolabelled with antibody against iNOS (E) and macrophage
marker MOMA-2 (F), showing significant necrosis of the tumour tissue and macrophages within and around the tumour expressing iNOS (bar = 40 ,um)
Calcium-independent NOS activity in peritoneal macrophages
from tumour-bearing mice after treatment with 5,6-MeXAA
(27.5 mg kg-') was increased from 2 pmol min-' mg-' protein to 16
(12 h after treatment) and 31 (3 days after treatment). The
increases were lower than those caused by two other immuno-
stimulatory compounds, LPS (71 pmol min-' mg-' protein 8 h after
treatment) and Corynebacterium parvum (92 pmol min-' mg-'
protein 7 days after treatment) in macrophages from control, non-
tumour-bearing animals.
Immunohistochemical localization of iNOS in the
tumour
Before treatment with 5,6-MeXAA, iNOS activity was present in
endothelial cells of the tumour as defined by the CD31 antibody
(Figure 2A,B). Some macrophages around the capsule, as defined
by the macrophage marker MOMA-2, also stained positively for
iNOS (Figure 2C and D). Twelve hours, 1, 3 and 7 days after treat-
ment with 5,6-MeXAA, significant necrosis in the tumour and
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Figure 4 5,6-MeXAA-induced accumulation of NOx in plasma in tumour-
bearing and control B6D2F1 mice. Mean ± s.e.m. (n = 6). 0, 5,6-MeXAA
27.5 mg kg-1 i.p. in tumour-bearing mice; *, 5,6-MeXAA 27.5 mg kg-' i.p. in
control mice; E, 5,6-MeXAA 40 mg kg-' i.p. in control mice
*32
Figure 3 The time-response curves of the stimulatory effects of 5,6-MeXAA
(A) and LPS (B) on plasma NOx concentrations in normal B6D2F1 mice.
Mean ± s.e.m. (n = 6). (A) *, 5,6-MeXAA 40 mg kg-' s.c.; *, 5,6-MeXAA
40 mg kg-' i.p.; *, 5,6-MeXAA 27.5 mg kg-' i.p.; 0, 5,6-MeXAA 27.5 mg kg-'
L.p. + L-NIO (30 mg kg-' before and 100 mg kg-' 5 h after 5,6-MeXAA). (B) *,
LPS (4 mg kg-') i.p.; 0 LPS (4 mg kg-') i.p. + L-NIO (30 mg kg-' before and
100 mg kg-' 5 h after LPS)
infiltrated macrophages were noted, with a marked reduction in
endothelial cells. Macrophages within and around the tumour
expressed iNOS at 12 h, 1, 3 and 7 days after 5,6-MeXAA treat-
ment (example at 3 days, Figure 2E and F). Expression ofiNOS by
tumour cells was not observed at any time.
Increase in plasma NOx concentrations
5,6-MeXAA increased plasma NOx in control, non-tumour-
bearing mice after i.p. and s.c. administration, reaching peak
concentrations 8-12 h after dosing (Figure 3A). Plasma NOx
concentrations returned to their initial levels within 24 h after 5,6-
MeXAA injections. The increase in plasma NOx was inhibited by
L-NIO, an inhibitor of NOS, in a dose-dependent manner. L-NIO
completely blocked increases in plasma NOx when it was given
at 30 mg kg-' before and 100 mg kg-' 5 h after 5,6-MeXAA
(27.5 mg kg-' i.p.) (Figure 3A). A lower dose ofL-NIO (30 mg kg-'
before and 30 mg kg-' 5 h after 5,6-MeXAA) reduced plasma NOx
concentrations measured 12 h after 5,6-MeXAA administration by
83%. The corresponding inhibitory action was 68% when L-NIO
was given in two 10 mg kg-' doses. Thetime course andthe increase
in plasma NOx concentrations induced by 5,6-MeXAA was similar
to those caused by LPS (4 mg kg-') (Figure 3B).
The maximal tolerated doses of5,6-MeXAA in tumour-bearing
B6D2F1 mice were lower (27.5 mg kg-') than in non-tumour-
bearing controls (40 mg kg-'). The effect of 5,6-MeXAA on
plasma NOx was greater in tumour-bearing than in control mice
(Figure 4).
As measured in control mice, the increase in plasma NOx was
preceded by a moderate increase in plasma TNF concentrations
and haematocrit (Figure 5) and accompanied by a rise in plasma
urea levels and the appearance of the liver enzymes GLDH and
ALT in the plasma (Table 2).
Effects of L-NIO on the tumoricidal action of 5,6-MeXAA
To understand the role of NO in the tumoricidal action of 5,6-
MeXAA, mice with subcutaneous colon 38 tumours were treated
with L-NIO. A dosing schedule of 60 mg kg-' twice a day s.c. was
used. This was based on the inhibitory effects of similar dosing
regimens ofL-NIO on the increase in plasma NOx induced by 5,6-
MeXAA and LPS (see results described above and Figure 3). The
first dose was injected 2 h after 5,6-MeXAA and this was repeated
at 12-h intervals for 7 days thereafter. Treatment with this regimen
of L-NIO did not alter the tumoricidal activity of 5,6-MeXAA
(Figure 6).
DISCUSSION
Treatment with 5,6-MeXAA increased NO production, as
evidenced by increased NOS activity in the tumour and some other
tissues and by enhanced NOx concentrations in plasma. Calcium-
independent but not calcium-dependent NOS activity was
increased, indicating induction of iNOS (Knowles et al, 1994).
British Journal of Cancer (1998) 77(3), 426-433
A
1O00
800
.40
200
I
i.
lI
0
B
*1"
-; :s .. I,.
400
0. 0 tO RO
ThwaBwLPSUt)
0 Cancer Research Campaign 1998Nitric oxide induction by5,6-MeXAA 431
1000
I'
600.
j.400
200
0:
I
-3.0
-2.5
-2.0
-1.5 ;PI
3
.'
-1.0 3
-0.5
-0
Tuneaft 5,6MeXAA (h)
Figure 5 Time courses of the effects of 5,6-MeXAA (40 mg kg-' i.p.) on TNF concentrations in plasma (@), haematocrit (0) and the accumulation of NOx in
plasma (U) in normal B6D2F1 mice. Mean ± s.e.m. (n = 6)
Table 2 Effects of 5,6-MeXAA (40 mg kg-' i.p.) on plasma NOx
concentrations and indicators of liver and kidney function in normal B6D2F1
mice
Before 12 h after 24 h after
Parameter 5,6-MeXAA 5,6-MeXAA 5,6-MeXAA
NOx (gM) 73 ± 13a 866 ±80***b 133 ± 19
Urea (mM) 7.5 ± 0.7 14.9 ± 1.3*** 10.0 ± 0.7
Creatinine (gM) 39.4 ± 1.7 36.0 ± 2.1 33.0 ± 2.0
ALT (U ml-') 30.6 ± 1.7 73.6 ± 10.2** 43.3 ± 4.1
GLDH (U ml-') 6.6 ±0.7 16.2 ± 1.4*** 12.3 ±2.3*
aMean ± s.e.m. n = 5 or 6 mice per group; bDifferences from corresponding
value before 5,6-MeXAA are denoted by *P < 0.05, **P< 0.01 and
***P< 0.001.
The increase in calcium-independent NOS activity was evident in
immunologically active organs (i.e. thymus, spleen, small intes-
tine) and in peritoneal macrophages as well as in the tumour.
Immunostaining showed that the predominant cell type in the
tumour that stained with the iNOS antibody was the infiltrating
macrophages, but not the tumour cell itself. This provides further
evidence that at least in this model it is the immune cells that
generate NO after treatment with 5,6-MeXAA.
The time-course as well as the tissue selectivity ofthe induction
of iNOS activity by 5,6-MeXAA was quite distinct from those of
other immunostimulatory agents known to induce iNOS. 5,6-
MeXAA induced NOS activity in thymus, spleen, small intestine
and in the tumour but not in other tissues such as lung, liver and
heart and thus differs from the action of LPS, muramyl dipeptide
and heat-inactivated Corynebacterium parvum (Palacios et al,
1992; Cunha et al, 1994; Rees et al, 1995). Induction ofiNOS was
present a few hours after treatment with 5,6-MeXAA, LPS or
myramyl dipeptide, whereas administration of heat-inactivated
Corynebacteriumparvum induced NO synthase with a time course
of several days (Palacios et al, 1992; Cunha et al, 1994; Rees
et al, 1995). The iNOS immunoreactivity in the tumour after
treatment with 5,6-MeXAA was associated with macrophages.
However, iNOS activity in peritoneal macrophages induced by
5,6-MeXAA was low compared with the activity in macrophages
after treatment with LPS or Corynebacterium parvum. These data
suggest that the role of NO as an effector mechanism in activated
macrophages and other target cells is different depending on the
immunostimulant used.
In vitro, 5,6-MeXAA is able to induce NO synthesis in mouse
peritoneal macrophages activated by Bacillus Calmette-Guerin but
not in resident or thioglycollate-elicited macrophages (Thomsen et
al, 1990). These data suggest that 5,6-MeXAA alone is not a suffi-
cient stimulus to induce iNOS in murine macrophages but that
other activating or priming agents are required. The increase in
plasma NOx concentrations was higher in tumour-bearing than
non-tumour-bearing animals after equivalent doses of 5,6-
MeXAA. The same phenomenon has been reported after treatment
with flavone-8-acetic acid, a compound related to 5,6-MeXAA
(Thomsen et al, 1991). This could be due to NO production in the
tumour cells as well as due to tumour-induced activation of the
immune cells (Scheiber et al, 1995) leading to higher response to
-immunostimulatory agents. In earlier experiments (Thomsen et al,
1991), the higher increase in plasma NOx after 5,6-MeXAA in
tumour-bearing animals was present, although the tumours were
cut outjust before the treatment with 5,6-MeXAA. In the present
study, iNOS was induced in tumour-associated macrophages but
not in the tumour cells. These data suggest that NO production in
the tumour cells does not explain the higher response in plasma
NOx after 5,6-MeXAA in tumour-bearing mice than in control
mice. Immunoreactive tissues such as spleen, thymus and lymph
nodes may be a source of increased plasma NOx. However, in
separate studies, we have been unable to detect increased iNOS
activity in spleen from tumour-bearing compared with non
tumour-bearing mice (LL Thomsen, unpublished observation). It
could therefore be hypothesized that tumour antigens and/or
products provide the priming stimuli required for 5,6-MeXAA to
elicit iNOS induction in the tumour-associated macrophages
and immunologically active organs.
The response to treatment with 5,6-MeXAA was characterized
by high concentrations of plasma NOx that peaked 8-12 h after
injection of the compound and was associated with biochemical
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Figure 6 Effects of L-NIO on the anti-tumour action of 5,6-MeXAA. Animals
with subcutaneously growing colon 38 tumours were treated with 5,6-MeXAA
on day 0 (27.5 mg kg-' i.p.) (C), 5,6-MeXAA (27.5 mg kg-' i.p.) followed by
L-NIO (60 mg kg-' s.c. twice a day for 7 days from day 0) (V) or with vehicle
only (0). Mean ± s.e.m. (n = 8)
alterations (ie. greater than twofold increases from basal levels of
plasma urea, and liver enzymes ALT and GLDH) and clinical
signs such as lethargy and dyspnoea, found in septic shock-like
syndrome. These biochemical and clinical signs, plasma NOx
concentrations, as well as NOS activity in thymus and spleen,
returned towards their initial levels in 24 h, whereas the NOS
activity in the tumour macrophages continued to increase and
reached its peak at 3 days after treatment with 5,6-MeXAA.
Tumour-associated macrophages have a pleiotropic function in the
regulation of tumour growth (Mantovani et al, 1992). These cells
produce growth factors and stimulate angiogenesis, thus
augmenting tumour growth. In contrast, tumour-associated
macrophages can be activated to inhibit tumour growth and
destroy neoplastic cells (Mantovani et al, 1992). The potential
tumoricidal mechanisms of activated macrophages in vitro include
increased synthesis of NO (Hibbs et al, 1987; Cox et al, 1992;
Lorsbach et al, 1993). However, recent studies with transfected
tumour cell lines constitutively expressing iNOS at relatively low
levels, have demonstrated that NO augments tumour growth in
vivo probably because of enhanced angiogenesis (Jenkins et al,
1995). To understand the role of enhanced NO synthesis in
tumour-associated macrophages after treatment with 5,6-MeXAA,
the animals were treated with a combination of5,6-MeXAA and L-
NIO, an inhibitor ofNOS enzymes. L-NIO at the regime given did
not alter significantly the tumoricidal activity of 5,6-MeXAA,
suggesting that NO may not be a major mediator in the anti-
tumour action of 5,6-MeXAA. A lack of effect of NOS inhibitors
on the tumour necrosis caused by some derivatives of flavone
acetic acid and TNF has been reported by Veszelovszky et al
(1993). However, the haemodynamic effects of L-NIO acting on
eNOS in the vasculature may contribute to the response and
further studies with selective inhibitors of iNOS or with iNOS
knock-out mice are needed to establish definitively what the role
of NO is in the tumoricidal action of5,6-MeXAA.
Increased concentrations of plasma NOx have been measured
during cancer immunotherapy with interleukin 2 (Hibbs et al,
1992; Ochoa et al, 1992; Thomsen et al, 1992; Miles et al, 1994)
and increased NO production has been associated with the side-
effects of this cytokine (Kilbourn et al, 1994; Miles et al, 1994).
Thus, combining a NOS inhibitor with cancer immunotherapy
with agents such as interleukin 2 and 5,6-MeXAA, which them-
selves increase NOS activity, provides a theoretical means to
diminish the side-effects and/or increase maximal tolerated doses
to achieve a better anti-tumour action.
In conclusion, an experimental anti-tumour agent 5,6-MeXAA,
which has been selected for clinical evaluation, was shown to
induce NO synthesis in immunologically active tissues and in
tumour-associated macrophages. Further experiments are needed
to understand the role, ifany, ofenhanced NOS activity in the anti-
tumour action or side-effects of 5,6-MeXAA.
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